Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.45 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | PPARG | P37231 | 1/20 | 0.37 |
| ▸ | CTBP2 | P56545 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | CES1 | P23141 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21087161 | 0.84 | HDAC1 (0.36) | HDAC8HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL19369663 | 0.81 | HDAC3 (0.48) | HDAC8HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL18751674 | 0.80 | CES1 (0.46) | HPGDKDM4ECES1L3MBTL1CA2 | |
| SCHEMBL13754456 | 0.79 | CA2 (0.50) | HDAC8HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL21118382 | 0.77 | HDAC3 (0.45) | HDAC8HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL14551994 | 0.77 | CYP4F2 (0.53) | HDAC8HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL11389533 | 0.76 | HPGD (0.55) | HPGDCTBP2CES1L3MBTL1 | |
| SCHEMBL17585416 | 0.76 | HDAC3 (0.43) | HDAC8HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL14189703 | 0.75 | HDAC3 (0.45) | HDAC8HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL21087395 | 0.74 | CYP1A2 (0.35) | HPGDPPARGCTBP2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190175744-A1 | INSULIN-INCRETIN CONJUGATES | MERCK SHARP & DOHME CORP. (US) | 2019-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190175744-A1 | INSULIN-INCRETIN CONJUGATES | GIPR, GLP1R, GCGR | HDAC8 1491/4885HDAC3 1100/4885HDAC1 1518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.